Stockscreener 앱 받기
0.58
1.72%
0.0098
시간 외 거래:
.58
전일 마감가:
$0.5702
열려 있는:
$0.5702
하루 거래량:
12,273
Relative Volume:
0.14
시가총액:
$3.49M
수익:
$14.64M
순이익/손실:
$-13.74M
주가수익비율:
-0.0798
EPS:
-7.27
순현금흐름:
$-5.04M
1주 성능:
-3.33%
1개월 성능:
-4.92%
6개월 성능:
+5.26%
1년 성능:
-78.48%
1일 변동 폭
$0.5702
$0.5872
1주일 범위
$0.5601
$0.61
52주 변동 폭
$0.3611
$9.079
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
명칭
Novabay Pharmaceuticals Inc
전화
510-899-8800
주소
2000 Powell Street, Suite 1150, Emeryville, CA
NBY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
0.58 | 3.49M | 14.64M | -13.74M | -5.04M | -7.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-09-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-15 | 재확인 | Laidlaw | Buy |
| 2017-06-05 | 개시 | ROTH Capital | Buy |
| 2017-03-27 | 개시 | Laidlaw | Buy |
| 2017-02-06 | 개시 | Rodman & Renshaw | Buy |
| 2016-03-07 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-12-14 | 재확인 | Maxim Group | Buy |
| 2015-04-30 | 재개 | Maxim Group | Buy |
| 2013-03-06 | 개시 | Ascendiant Capital Markets | Strong Buy |
| 2008-01-03 | 개시 | Dawson James | Speculative Buy |
모두보기
Novabay Pharmaceuticals Inc 주식(NBY)의 최신 뉴스
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
NovaBay Pharmaceuticals approves liquidation plan By Investing.com - Investing.com Canada
NovaBay Pharmaceuticals approves liquidation plan - Investing.com
Poplar Point Capital Partners acquires $39,503 in NovaBay shares - Investing.com Australia
Poplar Point Capital Partners increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com South Africa
Massive Stock Acquisition: Poplar Point Capital Partners Bets Big on NovaBay Pharma! - TipRanks
Poplar Point Capital Partners acquires $29,857 in NovaBay shares - Investing.com Australia
Poplar Point Capital increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com India
Poplar Point Capital Partners acquires $39,503 in NovaBay shares By Investing.com - Investing.com India
Poplar Point Capital Partners acquires $29,857 in NovaBay shares By Investing.com - Investing.com Canada
Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions - Investing.com
Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions By Investing.com - Investing.com UK
Poplar Point Capital increases stake in NovaBay Pharmaceuticals - Investing.com
NovaBay Pharmaceuticals sees $67,700 stock acquisition by Poplar Point Capital - Investing.com India
NovaBay Pharmaceuticals Inc. (NBY) reports earnings - qz.com
NovaBay Pharmaceuticals Delays Yearly Report Filing - TipRanks
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Revolutionizing Healing: Trends in the Advanced Wound Care Market with NovaBay, Healthy.io - openPR.com
Blepharitis Treatment Market Future Business Opportunities - openPR.com
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Sees Significant Decrease in Short Interest - Defense World
NovaBay Pharmaceuticals (NBY) Projected to Post Quarterly Earnings on Tuesday - Defense World
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Share Price Passes Above 50-Day Moving Average – Time to Sell? - Defense World
NovaBay reaches settlements over disputed warrants By Investing.com - Investing.com Australia
NovaBay reaches settlements over disputed warrants - Investing.com India
NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Novabay Pharmaceuticals Engages Financial Advisor Should Stockholders Fail To Approve Dissolution Proposal - Marketscreener.com
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders - Business Wire
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Update - Defense World
StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World
Investor Network: NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
NovaBay's Avenova Highlighted in National Dry Eye Awareness Month - ACCESS Newswire
NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World
NovaBay extends CEO's contract through 2025 - MSN
StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell? - Armenian Reporter
NovaBay fails to gain shareholder approval for dissolution - MSN
NovaBay fails to gain shareholder approval for dissolution By Investing.com - Investing.com Canada
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com - Defense World
**NovaBay Pharmaceuticals Completes Asset Sale Transaction and Plans for Dissolution**** - Defense World
NovaBay Pharmaceuticals Completes the Sale of its Avenova Eyecare Business to PRN, Seeks Full Company Dissolution - Vision Monday
NovaBay Pharma’s Strategic Shift and Liquidation Plans - TipRanks
Novabay Pharmaceuticals Inc (NBY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):